New antimicrobial approaches to gram positive respiratory infections

Liapikou, Adamantia; Cillóniz, Catia

doi:10.1016/j.pupt.2014.05.003

Cited by 16 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A clinical study (phase II) regarding the safety and efficacy of nemonoxacin in diabetic foot infections was completed [ 203 , 204 ]. As a result, the FDA authorized oral administration of nemonoxacin to treat CAP and bacterial skin infections [ 166 , 205 , 206 ].…”

Section: Compounds In Therapy Since 2000mentioning

confidence: 99%

Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation

et al. 2021

View full text Add to dashboard Cite

The evolution of the class of antibacterial quinolones includes the introduction in therapy of highly successful compounds. Although many representatives were withdrawn due to severe adverse reactions, a few representatives have proven their therapeutical value over time. The classification of antibacterial quinolones into generations is a valuable tool for physicians, pharmacists, and researchers. In addition, the transition from one generation to another has brought new representatives with improved properties. In the last two decades, several representatives of antibacterial quinolones received approval for therapy. This review sets out to chronologically outline the group of approved antibacterial quinolones since 2000. Special attention is given to eight representatives: besifloxacin, delafoxacin, finafloxacin, lascufloxacin, nadifloxacin and levonadifloxacin, nemonoxacin, and zabofloxacin. These compounds have been characterized regarding physicochemical properties, formulations, antibacterial activity spectrum and advantageous structural characteristics related to antibacterial efficiency. At present these new compounds (with the exception of nadifloxacin) are reported differently, most often in the fourth generation and less frequently in a new generation (the fifth). Although these new compounds’ mechanism does not contain essential new elements, the question of shaping a new generation (the fifth) arises, based on higher potency and broad spectrum of activity, including resistant bacterial strains. The functional groups that ensured the biological activity, good pharmacokinetic properties and a safety profile were highlighted. In addition, these new representatives have a low risk of determining bacterial resistance. Several positive aspects are added to the fourth fluoroquinolones generation, characteristics that can be the basis of the fifth generation. Antibacterial quinolones class continues to acquire new compounds with antibacterial potential, among other effects. Numerous derivatives, hybrids or conjugates are currently in various stages of research.

show abstract

Section: Compounds In Therapy Since 2000mentioning

confidence: 99%

Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Gram pozitif respiratuvar organizmalar arasında penisiline dirençli S.pneumoniae ve makrolid ve metisiline dirençli S.aureus en büyük tedavi zorluğunu oluşturan gruplar olup, penisilin dirençli S.pneumoniae oranları Asya'da % 50'lere dek çıkabilmekte, Akdeniz ülkelerinde ise % 25 dolaylarında seyretmektedir (42) . Penisiline dirençli S.pneumoniae suşlarının dünya genelinde eş-zamanlı olarak tetrasiklin, eritromisin ve kloramfenikole de direnç göstermesi ve S.pneumoniae için makrolid direnç oranlarının dünya genelinde %18-75 dolaylarında seyretmesi ayrıca önemlidir (38) . Çapraz direnç nedeniyle eritromisine dirençli suşlar klaritromisin, azitromisin gibi diğer makrolid grubu antibiyotiklere de dirençli olurla r (20)(21)(22)26,85) .…”

Section: Akut Otitis Media (Aom)unclassified

“…Klinik tanı sonrası başlangıç ampirik antibiyotik tedavisi için önerileri şöyle özetlenebilir (38) :…”

Section: Akut Bakteriyel Rinosinüzit (Abrs)unclassified

Antimicrobial Resistance in the Planning of the Empirical Therapy of Upper Respiratory Tract Infections: Current Situation and Treatment Strategies in Turkey and in the World

Hacımustafaoğlu¹,

Gürler²,

Ünal³

2018

Ankem Derg

View full text Add to dashboard Cite

Antimikrobiyal direnç (AMD) kötü klinik sonuçlar, artmış rekürren infeksiyon ve ölüm riski nedeniyle çok önemli, dünya genelinde prevalansı hızla artan bir sorundur. Son yıllarda aşırı ve akılcı olmayan antibakteriyel kullanımına bağlı artan direnç gelişimi sorununa karşın gelişen teknolojiye rağmen yeni bir antibakteriyel ilaç kullanıma alınamamıştır. Bu durum AMD probleminin hızla büyümesine neden olmaktadır. Türkiye ESAC-Net kapsamındaki tüm Avrupa ülkeleri arasında en yüksek oranda antibakteriyel ilaç kullanımına sahip ülke konumundadır. Solunum yolu infeksiyonları oldukça yaygın ve yüksek antibiyotik kullanım oranları açısından hastane kaynaklı infeksiyonlarda olduğu kadar, toplum kaynaklı infeksiyonların tedavisi için de süregiden bir sorun ve AMD önleme stratejileri için zorlu bir alandır. Gerek birinci basamak gerekse hastane düzeyinde aşırı ve akılcı olmayan antibiyotik kullanımının önüne geçilmesi için alınacak tedbirlerin AMD ile mücadelede rolü büyüktür. Bu derlemede, üst solunum yolu infeksiyonlarının ampirik tedavisinin planlamasında genelde göz ardı edilen AMD, Türkiye ve dünyadaki mevcut durum ve mücadele stratejileri açısından ele alınacaktadır.

show abstract

“…Telavancin (TLV) also has activity against PVL producing and nonproducing CA MRSA strains with a MIC 90 of 0.5 μg /mL, which is the same for vancomycin (30,36).…”

Section: Telavancinmentioning

confidence: 99%

Emerging drugs for nosocomial pneumonia

Liapikou

Torres

2016

Expert Opinion on Emerging Drugs

Self Cite

View full text Add to dashboard Cite

show abstract

New antimicrobial approaches to gram positive respiratory infections

Abstract: An improved and efficient method for the preparation of torezolid based on Suzuki cross-coupling reaction as the key step was developed on a gram scale in five steps. The total yield was 44% and the optical purity of torezolid by the improved method was above 99%.

Cited by 16 publications

References 47 publications

Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation

Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation

Antimicrobial Resistance in the Planning of the Empirical Therapy of Upper Respiratory Tract Infections: Current Situation and Treatment Strategies in Turkey and in the World

Emerging drugs for nosocomial pneumonia

Contact Info

Product

Resources

About